Are you ready to transform your patent practice?
Patent prosecution is complex – we know. If you’re ready for simpler workflows and more predictable outcomes, give us a call.
(gradient)+(2).png?width=2188&height=463&name=Juristat_Primary+(white+text)(gradient)+(2).png "Juristat | Patent analytics & workflow automation")
(gradient).png?width=2188&height=463&name=Juristat_Primary+(grey+text)(gradient).png "Juristat | Patent analytics & workflow automation")
Danielle Hohmeier
Director of Marketing at Juristat
Juristat Announces Investment Partnership with MBM Capital
Juristat, the St. Louis-based startup that helps patent lawyers improve strategic decision-making and automate workflows, is excited to announce a game-changing investment partnership with MBM Capital, launching the company into a new phase of growth.
The Most Difficult Examiners at the USPTO (2023)
When it comes to patent prosecution, knowing your examiner’s allowance rate can give you a great insight into the road that lies ahead.
Six Key Trends From Juristat’s 2022 Top Patent Firms
Time to dive deeper into key trends behind this year’s rankings.
USPTO Delays Switch to DOCX Filings…Again
The USPTO first announced in August 2020 that it would be imposing a new fee for patent applications not filed in DOCX format beginning on January 1, 2022. After multiple extensions, the USPTO announced that the deadline is now June 30, 2023.
USPTO Going All-In on DOCX Filings
The USPTO recently published a final rule announcing that it would encourage the transition to filing in DOCX format by imposing new fees on certain documents submitted in a non-DOCX format. The new rule takes effect on April 3, 2023.*
Most-Read Posts of 2022
2022 was an exciting year for Juristat. We launched new products like PTAB Expert Search, expanded our industry-leading analytics with 102 Forward Cite Reports, and improved our cutting-edge workflow automation tools to include Juristat OAR with Detailed Figure Annotations.
How COVID-19 Affected International Patent Filings
A new study from the Centre for Economic Policy Research tracks the COVID-19 pandemic’s effects on international patent filings and comes up with some surprising results.
USPTO Extends Patents 4 Patients Program Through January 2023
In 2016, the USPTO launched the Patents 4 Patients program to support the $1 billion National Cancer Moonshot initiative. In September of this year, the USPTO announced that the pilot program would be extended through January 31, 2023.
2022 Mid-Year Patent News Update
We are nearing the halfway point of 2022, with a new director at the USPTO, another opportunity to clarify the §101 patent eligibility framework, and a pair of bills poised to innovate the semiconductor industry. Here’s what you need to know about the year in patents so far.
